• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 38Comparison of the costs for the PenTAG AR,2 BMS3 and Novartis4 models compared with the base treatment

ModelDasatinibNilotinibHDIBase treatmenta
Drug costs (£) (discounted)PenTAG2161,43270,14388,88315,936
BMS3224,268228,576254,0186764
Novartis462,36367,94774,418
Other costs (£) (discounted)PenTAG259,89391,18783,53282,882
BMS390,14590,40296,347122,528
Novartis476,85378,2876515
Treatment duration (months) (undiscounted)PenTAG264272721
BMS38886789
Novartis42421

HDI, high-dose imatinib; HU, hydroxycarbamide; IFN-α, interferon alfa; SCT, stem cell transplantation.

a

Base treatment is IFN-α for PenTAG2 and BMS3 studies and HU-SCT for Novartis4 study.

Base treatment is IFN-α for PenTAG2 and BMS3 studies and HU-SCT for Novartis4 study.

From: 4, Economic analysis

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.